Reflux and dyspeptic symptom patterns in patients with non erosive reflux disease (NERD) subclassified using 24-hour ambulatory intraluminal pH-Impedance by Savarino, E. et al.
A
G
A
A
bs
tra
ct
s
markedly improved (from 10 to 16 mm) but the DS only mildly improved (from 32 to 30).
Discordant results were recorded in two patients. One patient had a 7 mm stricture with
DS 61 initially, and at follow up had a 5 mm diameter stricture with improved DS of 12.
In the final patient, the initial diameter was 9.8 mm with DS of 39. At repeat EGD the
stricture was measured as 16 mm diameter but the DS was the same at 39, and hence, did
not reflect improvement. Conclusions: The MDQ-30 can be used in research and clinical
practice to calculate a DS that is responsive and demonstrates excellent predictive validity.
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The Relationship Between Nasopharyngeal pH Environment and
Gastroesophageal Reflux
Daniel Luger, John E. Pandolfino, Peter J. Kahrilas, Anita Fareeduddin, Monika A.
Kwiatek
Background: Laryngopharyngeal reflux may contribute to supraesophageal symptoms such
as chronic cough, hoarseness and throat clearing. However, little is known about the extent
of acidification of the pharyngeal area and its relationship to gastroesophageal reflux. Aim: To
determine the correlation between gastroesophageal reflux events detected by multichannel
intraluminal impedance-pH (MII-pH) and nasopharyngeal (NP) acidification measured by
the Dx-pH systems. Methods: 7 controls and 3 patients (5M, 22 - 58 yr) underwent
simultaneous monitoring with nasopharyngeal pH (Dx-pH Measurement System™, Restech)
and MII-pH (AccuTracpH-Z™, Sierra Scientific Instruments) monitoring systems for an
average 16h. The Dx-pH electrode was positioned behind the soft palate. The MII-pH probe
measured impedance at 6 locations along the esophagus (3, 5, 7, 9, 15 and 17 cm above
the manometrically localized LES) and pH 5 cm proximal to LES. The MII-pH and Dx-pH
recordings were sampled at 50 and 2 Hz, respectively. Both electrodes were calibrated at
pH 4 and 7. The automated NP reflux detection scheme of Dx-pH DataView™ signaled an
event when the pH dropped 10% from a 15 minute running average baseline pH. The 15
min preceding the onset of an NP reflux event was analyzed for presence of esophageal
reflux. Esophageal reflux events were defined as pH drop ≥ 1 pH unit and/or retrograde
bolus propagation seen on MII. Results: Dx-pH tracings typically showed an upright average
baseline pH 7 - 7.5 with frequent rapid deviations < 0.5 pH units. Supine tracings showed
smooth and gradual pH drops over extended periods with an indistinguishable baseline.
The median time NP pH < 5.5 when upright, pH < 5 and 4.5 when supine were 0%, 0.2%
and 0%, respectively. Prolonged NP acidification was noted in 3 subjects mainly when
supine (pH < 4.5: 70.7%, 21.8% and 4.0%). A total of 37 NP vs. 537 esophageal reflux
events were seen in 10 subjects. 2.7% NP events coincided only with a distal esophageal
pH drop, while 16.2% and 13.5% NP events coincided with an acidic and weakly acidic
impedance event. The remainder 67.6% had no corresponding GER events. Conclusion:
There is a weak temporal relationship between nasopharyngeal acidification and esophageal
acidic or weakly acidic reflux events. This disconnect indicates that nasopharyngeal acid-
ification and esophageal reflux pathophysiology may not parallel each other. The etiology
and clinical significance of nasopharyngeal acidification events is unclear and requires further
study in the context of detectable esophageal reflux.
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Reflux and Dyspeptic Symptom Patterns in Patients with Non Erosive Reflux
Disease (NERD) Subclassified Using 24-Hour Ambulatory Intraluminal pH-
Impedance
Edoardo Savarino, Daniel Pohl, Patrizia Zentilin, Giorgio Sammito, Elisa Marabotto, Luca
M. Sconfienza, Andrea Parodi, Simone Vigneri, Radu Tutuian, Vincenzo Savarino
Introduction: Patients with abnormal pH-monitoring, esophagitis or Barrett' Esophagus
complain more frequently of symptoms such as heartburn, regurgitation and epigastric pain
or burning than patients with normal pH-testing. Non Erosive Reflux Disease (NERD)
incorporates different subgroups which have been recently differentiated by means of pH-
impedance testing (MII-pH). Aim: To evaluate differences in reflux and dyspeptic symptoms
in different subgroups of NERD patients. Methods: We evaluated NERD patients off-PPI
therapy using ambulatory 24-hour MII-pH. Refluxate presence was measured at 3,5,7,9,15
and 17 cm and esophageal pH at 5 cm above the LES. We calculated distal esophageal acid
exposure time (AET), number of impedance-detected reflux episodes (acid, nonacid) and
symptom association probability (SAP). A validated Dyspepsia Questionnaire was used to
quantify individual patients symptoms before examination. Results:Data from 200 consecut-
ive patients (105F, median age 48yrs) were analyzed. Subgrouping according to AET and
symptom characteristics are detailed in table 1. Fifty-four patients with normal AET and
negative SAP were classified as functional heartburn (FH) patients. Conclusions: The
increased prevalence of dyspeptic symptoms in patients with normal acid exposure and
negative symptom association further supports classifying these patients in the group of
functional esophageal disorders.
Table 1. Reflux and dyspeptic symptoms patterns in NERD patients (n=200)
A-64AGA Abstracts
Statistical analysis a pH-POS vs. pH-NEG/SAP + p<0.05, b pH-POS vs. pH-NEG/SAP - p<0.05,
c pH-NEG/SAP + vs. pH-NEG/SAP - p<0.05
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A Placebo-Controlled Trial of Visilizumab in Patients with Intravenous (IV)
Steroid Refractory Ulcerative Colitis (UC)
William J. Sandborn, Jean-Frederic Colombel, Matthew Frankel, Daniel Hommes, James
Lowder, Lloyd Mayer, Scott E. Plevy, Pieter Stokkers, Simon Travis, Gert A. Van Assche,
Stephan R. Targan
Aim: To evaluate the efficacy of visilizumab, an antibody against CD3, for the induction
treatment of IV steroid refractory UC. Methods: 127 patients with severely active UC despite
5 days or more of IV steroids were randomized to visilizumab 5 mcg/kg (n=84) or placebo
(n=43) infusions X 2 days. Patients were converted to oral prednisone 40 mg and tapered
according to disease activity. The primary endpoint was induction of response (decrease in
the Mayo score of >/=3 points and a decrease in the rectal bleeding score of >/=1 or a rectal
bleeding score of 0-1) at day 45. Secondary end-points included remission (Mayo score </=
2 with no individual subscores >1) at day 45, mucosal healing (endoscopy subscore </=1)
at day 45, symptomatic response (Modified Truelove and Witts Severity Index score </=9
with a decrease of >/=3 points from baseline) at day 15, prednisone discontinuation, and
time to colectomy. Results: The proportion of patients in response at day 45 was 55% with
visilizumab and 47% with placebo, p=0.475. The proportion of patients in remission at day
45 was 8% with visilizumab and 9% with placebo, p=0.704. The proportion of patients
with mucosal healing at day 45 was 29% with visilizumab and 26% with placebo, p=0.799.
The proportion of patients with symptomatic response at day 15 was 82% with visilizumab
and 74% with placebo, p=0.244. The proportion of patients who discontinued prednisone
was 14% with visilizumab and 21% with placebo, p=0.255. The median time to colectomy
could not be calculated, 15 patients (18%) in the visilizumab group and 3 patients (7%)
in the placebo group had a colectomy, p=0.130. Among visilizumab treated patients, CD4+
T-cells decreased to a mean of 10 cells/mcL (approximately 90% recovered by day 90). The
proportion of patients with serious adverse events was 17% with visilizumab and 16% with
placebo. Infections related to study drug in the visilizumab group included herpes zoster
2%, CMV 1%, and oral candidiasis 1%. The proportion of patients with cardiac disorders
was 11.9% with visilizumab (including tachycardia 8.3% (likely due to cytokine release
syndrome), angina 1.2%, cardiomyopathy 1.2%, myocardial ischemia 1.2%) and 4.7% with
placebo (sinus bradycardia 2.3% and sinus tachycardia 2.3%). The proportion of patients
with vascular disorders was 22.6% with visilizumab (including phlebitis 2.4%, thrombophle-
bitis 2.4%, superficial thrombophlebitis 2.4%, deep vein thrombosis 1.2%, vasculitis 1.2%,
other 13%) and 4.7% with placebo (other 4.7%). Conclusions: Among patients with IV
steroid refractory UC, visilizumab was not effective and was associated with increased
infectious, cardiac, and vascular adverse events.
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Supplementation with the Probiotic VSL#3 in Patients with Mild-to-Moderate
Active Ulcerative Colitis: A Double-Blind, Randomized, Placebo-Controlled
Study
Antonio Tursi, Giovanni Brandimarte, Alfredo Papa, Andrea Giglio, Walter Elisei,
GianMarco Giorgetti, Giacomo Forti, Silvio Danese, Antonio Gasbarrini
Background: VSL#3 probiotic mixture has been show to be effective in supporting standard
treatments in active ulcerative colitis (UC) in open-label studies. Aims: Primary end-point of
the study was to asses the effect of the supplementation of VSL#3 to a standard pharmaceutical
treatment in patients affected by active UC, assessed by a decrease in the UC Disease Activity
Index (UCDAI) of 50% or more, from baseline to week 8. Secondary end-points were
considered: activity of UC, change in subjective symptoms (rectal bleeding and stool fre-
quency), lack of beneficial effects, concordance between the Physician and Patients Global
Assessment Scale, from baseline to week 8. Methods: 144 consecutive patients with diagnosis
of mild-to-moderate active UC, and already under treatment with stable doses of 5-ASA,
were randomly treated for 8 weeks with VSL#3 3600 billion/day (71 pts) or with placebo
(73 pts). UCDAI, and Physician and Patients Global Assessment Scale were assessed at
baseline and at week 8. Results: 65 pts in VSL#3 group and 66 pts in placebo group
completed the study; 4 pts (3 in VSL#3 group and 1 in the placebo group) were lost to
follow-up, 3 pts (2 in VSL#3 group and 1 in placebo group) withdrew consent to the study,
1 pt in VSL#3 group was withdrawn for protocol violation, 5 pts in placebo group were
withdrawn for lack of efficacy. As regards the primary endpoint, the decrease in UCDAI of
50% or more after 8 weeks was higher in VSL#3 than in placebo group (63.1 vs 42.9,
p<0.019). Looking at the secondary end-points, the number of pts who had an improvement
in the UCDAI of 3 point or more was significantly higher in VSL#3 than in the placebo
group (60.5% vs 41.4%, p<0.031); rectal bleeding improved significantly in VSL#3 than in
placebo group (p<0.017); stool frequency did not show statistical difference between the
two groups (50.8% vs 42.9%, p=n.s.); Physician and Patients Global Assessment Scale did
not show statistical difference between the two groups (p=n.s.). Finally, the number of pts
in remission was higher in VSL#3 than in placebo group (47.7% vs 32.9%, p=0.079).
Non side-effects were recorded both in VSL#3 and in placebo group. Conclusions: VSL#3
supplementation is safe and able to reduce UCDAI after 8 weeks of treatment use in patients
affected by mild to moderate UC. Moreover, VSL#3 improves rectal bleeding and it seems
to be able in inducing remission in UC patients after 8 weeks of treatment, though this
latter parameter is borderline significant.
